metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	2	statistically conclusive 42 % decrease in progression or deaths (PFS) suggested 90 % increase in objective responses (ORR)	inconclusive results for: DOR	statistically conclusive 22 % decrease in deaths (OS) but the degree if certainty is unassessable	-
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1	none	inconclusive results for: DOR	statistically conclusive 21 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 36 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 2.1-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin	1	none	inconclusive results for: deaths (OS); DOR; AE (any grade); AE (grade 3-4); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); SAE (any grade); STRAE (any grade); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); Colitis TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Pancreatitis TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Rash TRAE (grade 3-4); Severe skin reaction TRAE (grade 3-4)	statistically conclusive 40 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 86 % increase in objective responses (ORR) but the degree if certainty is unassessable	-
	pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin	1	none	inconclusive results for: deaths (OS); deaths (OS) (extension); DOR; DOR (extension); STRAE (any grade); STRAE (grade 3-4); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Acute kidney injury TRAE (grade 3-4); Alopecia TRAE (grade 3-4); Anaemia TRAE (grade 3-4); Blood creatinine increased TRAE (grade 3-4); Constipation TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dizziness TRAE (grade 3-4); Dysgeusia TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Increased lacrimation (TRAE grade 3-4); Infusion-related reactions TRAE (grade 3-4); Leucopenia TRAE (grade 3-4); Nausea TRAE (grade 3-4); Neutropenia TRAE (grade 3-4); Pancytopenia TRAE (grade 3-4); Peripheral oedema TRAE (grade 3-4); Pneumonia TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Sepsis TRAE (grade 3-4); Severe skin reaction TRAE (grade 3-4); Stomatitis TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Vomiting TRAE (grade 3-4)	suggested 46 % decrease in PFS (extension) but the degree if certainty is unassessable statistically conclusive 47 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 3.1-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 2.8-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	none	inconclusive results for: DOR; AE (any grade); AE (grade 3-4); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); AE leading to treatment discontinuation (grade 3-4); Adrenal insufficiency TRAE (grade 3-4); Colitis TRAE (grade 3-4); Diabetes TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypophysitis TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Myositis TRAE (grade 3-4); Nephritis TRAE (grade 3-4); Pancreatitis TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Severe skin reaction TRAE (grade 3-4); Thyroiditis TRAE (grade 3-4); Anaemia AE (grade 3-4); Asthenia AE (grade 3-4); Constipation AE (grade 3-4); Cough AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Dyspnoea AE (grade 3-4); Fatigue AE (grade 3-4); Lacrimation increased AE (grade 3-4); Nausea AE (grade 3-4); Neutropenia AE (grade 3-4); Peripheral oedema AE (grade 3-4); Pyrexia AE (grade 3-4); Rash AE (grade 3-4); Thrombocytopenia AE (grade 3-4); Vomiting AE (grade 3-4)	statistically conclusive 51 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 44 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable suggested 52 % decrease in PFS (extension) but the degree if certainty is unassessable statistically conclusive 48 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 3.9-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 3.8-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-